surmount-1 tirzepatide trial obesity without diabetes SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide vs semaglutide: A new
Description
0.4% for semaglutide) with discontinuation rates of 6-8.5% vs
Our team at Boca Medical Care would be happy to assist you in determining if Tirzepatide is a suitable method of weight loss for you and can create a personalized treatment plan to help you reach your weight-loss objectives
The study was a double-blind, placebo-controlled trial with participants receiving once-weekly subcutaneous doses of tirzepatide or a placebo
They may prescribe medication or another course of treatment
Tirzepatide works by targeting GLP-1 AND GIP receptors which stimulates the release of insulin and reduces the time for the stomach to empty its contents
Researchers later discovered that it also produces significant weight loss in many patients by reducing appetite and improving how the body regulates blood sugar
